• Acquisition of Mann-type glycans is a tumor-specific environmental pressure indicative of aggressive GCB-DLBCL with its origin related to FL.

  • Mann-type DLBCL can be diagnosed by the concomitant detection of AGSs in the CDR and a BCL2 translocation.

Abstract

The acquisition of N-glycosylation sites that are occupied by oligomannose-type glycans in the immunoglobulin complementarity–determining region (CDR) is an early, clonal, tumor-specific identifier of follicular lymphoma (FL). CDR-located N-glycosylation sites are also acquired in germinal center B-cell–like diffuse large B-cell lymphomas (GCB-DLBCLs), but their significance is less defined. We used RNA sequencing immunoglobulin assembly to determine frequency and CDR location of the acquired N-glycosylation sites (AGSs) in 2 independent DLBCL cohorts. Composition of the glycans occupying the AGSs was determined using liquid chromatography-mass spectrometry and correlated with cell of origin, FL signature (defined by EZB phenotype or BCL2 translocation), transcript profile, and clinical outcome. CDR-located AGSs were observed in 41% to 46% of GCB-DLBCLs but were rare in other DLBCLs. Only CDR-located AGSs of DLBCL with an FL signature were occupied by oligomannose-type glycans. These DLBCLs were termed Mann-type DLBCL. Conversely, the AGSs of the other DLBCLs were either nonglycosylated or occupied by complex-type glycans. Mann-type status was an independent marker of short progression-free survival and overall survival. In contrast, the other GCB-DLBCLs, including those with an FL signature but without AGSs, had the best outcomes. Mann-type DLBCLs overexpressed gene sets of cell growth, survival, and cycling, and underexpressed proinflammatory and apoptotic pathways, irrespective of the presence of concomitant MYC translocations. The acquisition of Mann-type glycans is a highly selective environmental pressure enabling the identification of an aggressive GCB-DLBCL type with origin related to FL. The detection of AGSs in the CDR of GCB-DLBCLs with an FL signature defines Mann-type DLBCLs, refines prognosis, and marks a precise tumor interaction to block early therapeutically.

1.
Lam
KP
,
Kühn
R
,
Rajewsky
K
.
In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death
.
Cell
.
1997
;
90
(
6
):
1073
-
1083
.
2.
George
AJ
,
Spellerberg
MB
,
Stevenson
FK
.
Idiotype vaccination leads to the emergence of a stable surface Ig-negative variant of the mouse lymphoma BCL1, with different growth characteristics
.
J Immunol
.
1988
;
140
(
5
):
1695
-
1701
.
3.
Varano
G
,
Raffel
S
,
Sormani
M
, et al
.
The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3beta inhibition
.
Nature
.
2017
;
546
(
7657
):
302
-
306
.
4.
Stevenson
FK
,
Forconi
F
,
Kipps
TJ
.
Exploring the pathways to chronic lymphocytic leukemia
.
Blood
.
2021
;
138
(
10
):
827
-
835
.
5.
Stevenson
FK
,
Forconi
F
.
The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells
.
Blood
.
2024
;
143
(
12
):
1091
-
1100
.
6.
Chiodin
G
,
Allen
JD
,
Bryant
DJ
, et al
.
Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior
.
Blood
.
2021
;
138
(
17
):
1570
-
1582
.
7.
Coelho
V
,
Krysov
S
,
Ghaemmaghami
AM
, et al
.
Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins
.
Proc Natl Acad Sci U S A
.
2010
;
107
(
43
):
18587
-
18592
.
8.
Linley
A
,
Krysov
S
,
Ponzoni
M
,
Johnson
PW
,
Packham
G
,
Stevenson
FK
.
Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells
.
Blood
.
2015
;
126
(
16
):
1902
-
1910
.
9.
Geijtenbeek
TB
,
Torensma
R
,
van Vliet
SJ
, et al
.
Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses
.
Cell
.
2000
;
100
(
5
):
575
-
585
.
10.
Soilleux
EJ
,
Morris
LS
,
Leslie
G
, et al
.
Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro
.
J Leukoc Biol
.
2002
;
71
(
3
):
445
-
457
.
11.
Radtke
AJ
,
Postovalova
E
,
Varlamova
A
, et al
.
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients
.
Cancer Cell
.
2024
;
42
(
3
):
444
-
463.e10
.
12.
Amin
R
,
Mourcin
F
,
Uhel
F
, et al
.
DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma
.
Blood
.
2015
;
126
(
16
):
1911
-
1920
.
13.
Savelyeva
N
,
King
CA
,
Vitetta
ES
,
Stevenson
FK
.
Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help
.
Proc Natl Acad Sci U S A
.
2005
;
102
(
31
):
10987
-
10992
.
14.
Valle-Argos
B
,
Chiodin
G
,
Bryant
DJ
, et al
.
DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity
.
Sci Rep
.
2021
;
11
(
1
):
11676
.
15.
Alizadeh
AA
,
Eisen
MB
,
Davis
RE
, et al
.
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
.
Nature
.
2000
;
403
(
6769
):
503
-
511
.
16.
Rosenwald
A
,
Wright
G
,
Chan
WC
, et al
.
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
.
N Engl J Med
.
2002
;
346
(
25
):
1937
-
1947
.
17.
Wright
GW
,
Huang
DW
,
Phelan
JD
, et al
.
A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications
.
Cancer Cell
.
2020
;
37
(
4
):
551
-
568.e14
.
18.
Wilson
WH
,
Wright
GW
,
Huang
DW
, et al
.
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
.
Cancer Cell
.
2021
;
39
(
12
):
1643
-
1653.e3
.
19.
Pasqualucci
L
,
Dalla-Favera
R
.
Genetics of diffuse large B-cell lymphoma
.
Blood
.
2018
;
131
(
21
):
2307
-
2319
.
20.
Green
MR
,
Kihira
S
,
Liu
CL
, et al
.
Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation
.
Proc Natl Acad Sci U S A
.
2015
;
112
(
10
):
E1116
-
E1125
.
21.
Pasqualucci
L
,
Dominguez-Sola
D
,
Chiarenza
A
, et al
.
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
.
Nature
.
2011
;
471
(
7337
):
189
-
195
.
22.
Okosun
J
,
Bödör
C
,
Wang
J
, et al
.
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma
.
Nat Genet
.
2014
;
46
(
2
):
176
-
181
.
23.
Ennishi
D
,
Jiang
A
,
Boyle
M
, et al
.
Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma
.
J Clin Oncol
.
2019
;
37
(
3
):
190
-
201
.
24.
Chapuy
B
,
Stewart
C
,
Dunford
AJ
, et al
.
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
.
Nat Med
.
2018
;
24
(
5
):
679
-
690
.
25.
Goyal
G
,
Magnusson
T
,
Wang
X
,
Roose
J
,
Narkhede
M
,
Seymour
E
.
Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double/triple-hit status in the United States
.
Haematologica
.
2023
;
108
(
4
):
1190
-
1195
.
26.
Phelan
JD
,
Young
RM
,
Webster
DE
, et al
.
A multiprotein supercomplex controlling oncogenic signalling in lymphoma
.
Nature
.
2018
;
560
(
7718
):
387
-
391
.
27.
Young
RM
,
Wu
T
,
Schmitz
R
, et al
.
Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens
.
Proc Natl Acad Sci U S A
.
2015
;
112
(
44
):
13447
-
13454
.
28.
Schmitz
R
,
Wright
GW
,
Huang
DW
, et al
.
Genetics and pathogenesis of diffuse large B-cell lymphoma
.
N Engl J Med
.
2018
;
378
(
15
):
1396
-
1407
.
29.
Bryant
D
,
Sale
B
,
Chiodin
G
, et al
.
Identification, assembly, and characterization of tumor immunoglobulin transcripts from RNA sequencing data using IgSeqR
.
Nat Protoc
.
Published online 24 April 2025
.
30.
McCann
KJ
,
Ottensmeier
CH
,
Callard
A
, et al
.
Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma
.
Mol Immunol
.
2008
;
45
(
6
):
1567
-
1572
.
31.
Allen
JD
,
Ivory
DP
,
Song
SG
, et al
.
The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2
.
Cell Rep
.
2023
;
42
(
4
):
112307
.
32.
Alduaij
W
,
Collinge
B
,
Ben-Neriah
S
, et al
.
Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population
.
Blood
.
2023
;
141
(
20
):
2493
-
2507
.
33.
Watanabe
Y
,
Bowden
TA
,
Wilson
IA
,
Crispin
M
.
Exploitation of glycosylation in enveloped virus pathobiology
.
Biochim Biophys Acta Gen Subj
.
2019
;
1863
(
10
):
1480
-
1497
.
34.
Loke
I
,
Kolarich
D
,
Packer
NH
,
Thaysen-Andersen
M
.
Emerging roles of protein mannosylation in inflammation and infection
.
Mol Aspects Med
.
2016
;
51
:
31
-
55
.
35.
Gazzola
A
,
Navari
M
,
Mannu
C
,
Donelli
R
,
Etebari
M
,
Piccaluga
PP
.
Single-step IGHV next-generation sequencing detects clonality and somatic hypermutation in lymphoid malignancies: a phase III diagnostic accuracy study
.
Cancers (Basel)
.
2023
;
15
(
18
):
4624
.
36.
McCann
KJ
,
Johnson
PW
,
Stevenson
FK
,
Ottensmeier
CH
.
Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event?
.
Leukemia
.
2006
;
20
(
3
):
530
-
534
.
37.
Scheich
S
,
Chen
J
,
Liu
J
, et al
.
Targeting N-linked glycosylation for the therapy of aggressive lymphomas
.
Cancer Discov
.
2023
;
13
(
8
):
1862
-
1883
.
38.
Pereira
CF
,
Torensma
R
,
Hebeda
K
, et al
.
In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model
.
J Immunother
.
2007
;
30
(
7
):
705
-
714
.
39.
Odabashian
M
,
Carlotti
E
,
Araf
S
, et al
.
IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution
.
Blood
.
2020
;
135
(
11
):
834
-
844
.
You do not currently have access to this content.
Sign in via your Institution